-9.3%
UL vs GSK
+31.2%
-40.5%
-25.1%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.1% | -1.9% | +1.9% | +0.4% |
| 7D | -1.3% | -1.8% | +0.5% | -0.9% |
| 30D | +0.5% | -2.2% | +2.7% | +1.0% |
| 3M | +17.6% | -1.8% | +19.4% | +18.2% |
| 6M | -5.4% | -10.6% | +5.2% | -3.6% |
| YTD | +0.7% | +4.4% | -3.7% | +1.7% |
| 1Y | -9.3% | +30.4% | -39.7% | -8.5% |
| All | -9.3% | +31.2% | -40.5% | -8.5% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling